DK2504357T3 - Rekombinante filaggrinpolypeptider til celleimport - Google Patents
Rekombinante filaggrinpolypeptider til celleimport Download PDFInfo
- Publication number
- DK2504357T3 DK2504357T3 DK10832312.2T DK10832312T DK2504357T3 DK 2504357 T3 DK2504357 T3 DK 2504357T3 DK 10832312 T DK10832312 T DK 10832312T DK 2504357 T3 DK2504357 T3 DK 2504357T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- gly
- arg
- gin
- glu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (14)
1. Rekombinant polypeptid, som omfatter (a) en filaggrinaminosyresekvens; og (b) en celleimportsignalsekvens, der omfatter et motiv af to til femten aminosyrer, hvor motivet omfatter mindst en argininrest og mindst en methionin-rest.
2. Polypeptid ifølge krav 1, hvor (a) filaggrinaminosyresekvensen omfatter SEQ ID NO:1, (b) motivet omfatter aminosyresekvensen af RM eller MR, (c) motivet omfatter SEQ ID NO:23, eller (d) polypeptidet omfatter SEQ ID NO:21 eller SEQ ID NO:22 eller fortrinsvis består af SEQ ID NO:21 eller SEQ ID NO:22.
3. Polypeptid ifølge krav 1, hvor polypeptidet desuden er defineret som et fusionsprotein af filaggrinaminosyresekvensen og celleimportaminosyrese-kvensen, eller hvor filaggrinaminosyresekvensen er bundet til N- eller C-terminussen af celleimportsignalsekvensen.
4. Sammensætning til anvendelse inden for hudpleje omfattende en virksom mængde af et polypeptid ifølge et af kravene 1 til 3.
5. Sammensætning ifølge krav 4, hvor sammensætningen omfatter en lipid-komponent, især et phospholipid, eller hvor sammensætningen omfatter 0,001 til 5,0 vægtprocent af polypeptidet.
6. Sammensætning ifølge krav 4, hvor sammensætningen er en opløsning, en creme, en lotion, en gel, en salve eller en emulsion, især en olie-i-vand-emulsion eller en vand-i-olie-emulsion.
7. Nukleinsyre, som omfatter en nukleinsyresekvens, der koder et polypeptid ifølge et af kravene 1 til 3.
8. Farmaceutisk sammensætning, som omfatter et polypeptid ifølge et af kravene 1 til 3.
9. Farmaceutisk sammensætning ifølge krav 8 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af en hudsygdom eller hudlidelse, hvor en stigning i intracellulært filaggrin er kendt eller formodes at være en fordel.
10. Sammensætning til anvendelse ifølge krav 9, hvor individet er et menneske, eller hvor hudsygdommen er ichthyosis vulgaris eller atopisk dermatitis.
11. Sammensætning til anvendelse ifølge krav 9, hvor sammensætningen er til topisk påføring på en hudoverflade af et individ, eller hvor sammensætningen endvidere omfatter mindst et yderligere middel, især et befugtningsmid-del, et eksfolieringsmiddel, et antiinflammatorisk middel eller et antimikrobielt middel.
12. Kit omfattende en forseglet beholder omfattende et rekombinant polypeptid ifølge et af kravene 1 til 3 eller en farmaceutisk sammensætning ifølge krav 8.
13. Kit ifølge krav 12, hvor den forseglede beholder er et hætteglas, en flaske, en dispenser eller en pakke, eller hvor kittet endvidere omfatter en ap-plikator.
14. Anvendelse af polypeptidet ifølge et af kravene 1 til 3 ved fremstillingen af et medikament til behandling eller forebyggelse af en hudsygdom eller hudlidelse, hvor en stigning i intracellulært filaggrin er kendt eller formodes at være en fordel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26360409P | 2009-11-23 | 2009-11-23 | |
PCT/US2010/057592 WO2011063320A2 (en) | 2009-11-23 | 2010-11-22 | Recombinant filaggrin polypeptides for cell importation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2504357T3 true DK2504357T3 (da) | 2017-10-23 |
Family
ID=44060387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10832312.2T DK2504357T3 (da) | 2009-11-23 | 2010-11-22 | Rekombinante filaggrinpolypeptider til celleimport |
Country Status (8)
Country | Link |
---|---|
US (3) | US10336797B2 (da) |
EP (1) | EP2504357B1 (da) |
AU (1) | AU2010321784B2 (da) |
CA (1) | CA2781537C (da) |
DK (1) | DK2504357T3 (da) |
ES (1) | ES2645416T3 (da) |
NO (1) | NO2504357T3 (da) |
WO (1) | WO2011063320A2 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140170180A1 (en) | 2012-12-17 | 2014-06-19 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5a, methods of use and vaccine |
US20140234354A1 (en) | 2013-02-15 | 2014-08-21 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5b, methods of use and vaccine |
WO2015061856A1 (en) * | 2013-10-30 | 2015-05-07 | University Of Western Australia | Neuroprotective peptides |
CA2979079A1 (en) | 2014-05-30 | 2015-12-03 | Azitra, Inc. | Therapeutic treatment of skin disease with recombinant commensal skin microorganisms |
EP3323827A1 (en) * | 2016-11-21 | 2018-05-23 | Christian-Albrechts-Universität zu Kiel | Cationic intrinsically disordered antimicrobial peptides |
KR102134414B1 (ko) | 2017-08-04 | 2020-07-15 | 주식회사 케이티 | 액세스 포인트의 신호 세기를 이용하여 위치를 측정하는 장치 및 방법 |
AU2018328119A1 (en) * | 2017-09-05 | 2020-04-02 | Azitra Inc | Methods and compositions for treating inflammatory skin disease with recombinant microorganisms |
AU2019249249A1 (en) * | 2018-04-05 | 2020-10-22 | Azitra Inc | Methods and compositions for treating skin disease with recombinant microorganisms |
US11414057B2 (en) * | 2019-04-03 | 2022-08-16 | GM Global Technology Operations LLC | Retractable pedal assembly for a vehicle |
CN113045638B (zh) * | 2021-04-01 | 2022-04-15 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种酿酒酵母表达长效重组人丝聚蛋白及其应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3463302A (en) * | 1967-09-20 | 1969-08-26 | Pearl M Preston | Packaged disposable lotion filled applicator |
DE69310339T2 (de) | 1993-02-19 | 1997-08-21 | Philippe Djian | Präparate, die Corneozyt Proteine enthalten |
US6852686B2 (en) | 1999-06-23 | 2005-02-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for ameliorating icthyosiform skin diseases |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
AU1159601A (en) | 1999-11-03 | 2001-05-14 | Metris Therapeutics Limited | Agents implicated in endometriosis |
AU2085502A (en) | 2000-11-30 | 2002-06-11 | Molecular Skincare Ltd | Diagnosis and treatment of disease |
JP2005508832A (ja) * | 2001-02-16 | 2005-04-07 | セルゲイト, インコーポレイテッド | 間隔を開けてアルギニン部分を含むトランスポーター |
GB0111324D0 (en) | 2001-05-09 | 2001-07-04 | Unilever Plc | Ambient stable beverage |
WO2003030857A1 (en) | 2001-10-04 | 2003-04-17 | Unilever Plc | Enhancing epidermal barrier development in skin |
KR100753472B1 (ko) | 2002-03-15 | 2007-08-31 | 주식회사 엘지생활건강 | 사람 콜라겐 ⅰ형의 c-말단에서 유래된 펩타이드에tat 펩타이드가 결합된 융합 펩타이드, 이의 제조방법,및 이를 포함하는 피부주름개선 화장료 조성물 |
IL157786A (en) | 2003-09-07 | 2010-11-30 | Ahava Dead Sea Lab Ltd | Personalized cosmetics |
KR100659138B1 (ko) | 2005-09-16 | 2006-12-19 | (주)아모레퍼시픽 | 유효성분으로 갈로카테킨 갈레이트를 함유하는 보습용피부외용제 조성물 |
US20090098074A1 (en) * | 2005-12-01 | 2009-04-16 | Basf Se | Keratin-Binding Effector Molecules Containing Reactive Dyes |
GB0525492D0 (en) | 2005-12-15 | 2006-01-25 | Univ Dundee | Filaggrin |
GB0600948D0 (en) | 2006-01-18 | 2006-02-22 | Univ Dundee | Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders |
JP6175236B2 (ja) | 2009-09-25 | 2017-08-09 | カッパーアールエヌエー,インコーポレイテッド | フィラグリン(flg)の発現および活性の調整によるflg関連疾患の処置 |
FR2968303B1 (fr) | 2010-12-07 | 2013-01-18 | Oreal | Peptides modulateurs du complexe saspase-flg2 |
-
2010
- 2010-11-22 US US13/511,267 patent/US10336797B2/en active Active
- 2010-11-22 NO NO10832312A patent/NO2504357T3/no unknown
- 2010-11-22 WO PCT/US2010/057592 patent/WO2011063320A2/en active Application Filing
- 2010-11-22 AU AU2010321784A patent/AU2010321784B2/en not_active Revoked
- 2010-11-22 ES ES10832312.2T patent/ES2645416T3/es active Active
- 2010-11-22 DK DK10832312.2T patent/DK2504357T3/da active
- 2010-11-22 EP EP10832312.2A patent/EP2504357B1/en active Active
- 2010-11-22 CA CA2781537A patent/CA2781537C/en active Active
-
2019
- 2019-01-08 US US16/242,487 patent/US11098097B2/en active Active
-
2020
- 2020-10-12 US US17/068,177 patent/US20210024600A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
NO2504357T3 (da) | 2017-12-30 |
US10336797B2 (en) | 2019-07-02 |
WO2011063320A2 (en) | 2011-05-26 |
US20130018000A1 (en) | 2013-01-17 |
US20190127430A1 (en) | 2019-05-02 |
AU2010321784A1 (en) | 2012-05-24 |
CA2781537A1 (en) | 2011-05-26 |
US11098097B2 (en) | 2021-08-24 |
CA2781537C (en) | 2022-06-28 |
AU2010321784B2 (en) | 2014-04-24 |
WO2011063320A3 (en) | 2011-11-03 |
EP2504357A2 (en) | 2012-10-03 |
ES2645416T3 (es) | 2017-12-05 |
US20210024600A1 (en) | 2021-01-28 |
EP2504357A4 (en) | 2013-09-04 |
EP2504357B1 (en) | 2017-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11098097B2 (en) | Recombinant filaggrin polypeptides for cell importation | |
KR101944388B1 (ko) | 피부 투과성 펩티드 및 그 이용방법 | |
KR101258279B1 (ko) | 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법 | |
JP6001082B2 (ja) | 細胞透過能を改善した改良形の新規巨大分子伝達ドメインの開発及びその利用方法 | |
KR20120034927A (ko) | 피부투과성 인간 상피세포 성장인자 및 그 생산방법 | |
EP3808762A1 (en) | Fusion protein bound to cell-permeable peptide, and composition comprising fusion protein or cell-permeable peptide and epithelial cell growth factor as active ingredients | |
AU2022218622A1 (en) | Nuclear-targeted dna repair enzymes and methods of use | |
US6800609B1 (en) | Isolated peptide of the horny layer and user thereof | |
AU2014203006B2 (en) | Recombinant filaggrin polypeptides for cell importation | |
EP4322984A1 (en) | Psg1 for use in the treatment of osteoarthritis | |
US10588939B2 (en) | Method of treating a bladder cancer using a chimeric EGF-targeted bacterial toxin | |
US20140303093A1 (en) | Micro-utrophin polypeptides and methods | |
KR101841241B1 (ko) | 피부 질환에 대한 예방 또는 치료효과를 갖는 펩티드 융합체 및 이를 유효성분으로 하는 약학 조성물 | |
EP2504027B1 (en) | Acceleration of wound healing by a tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi)-anchors | |
WO2022164823A2 (en) | Inhibition of degranulation of neutrophil cells in covid-19 patients | |
CN117561075A (zh) | 肉毒杆菌神经毒素的肌内注射组合物 | |
EP1097201A1 (de) | Snurportin1, humanes m3g-cap-spezifisches kernimportrezeptorprotein mit einer neuen domänenstruktur, dessen herstellung und verwendung |